Improving brain function impairment in people with substance use disorders (PSUD) is considered to be important in regulating their cyclic drug use impulse and relapse behavior. Physical exercise (PE) and repetitive transcranial magnetic stimulation (rTMS) may improve brain functional impairment in PSUD, respectively, but few studies have focused on the benefits and mechanisms of the combined use of the two. This editorial presents: 1) Both PE and rTMS alone appear to have positive effects on PSUD's reward system, cognitive function, and emotional regulation to varying degrees. 2) The mode of PE combined with rTMS seems to have a superimposed benefit on the brain function of PSUD by promoting the dynamic regulation of neurotransmitters and receptors, plasticity changes in neurogenesis and synapses, and the reversible development of brain structure and functional connections in PSUD. However, although this combination model provides a reference for subsequent targeted intervention therapy for drug use disorders, further studies are needed to provide more direct evidence of the corresponding benefits and mechanisms.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.genhosppsych.2025.01.001 | DOI Listing |
Neoplasma
December 2024
Department of Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast malignancy. Although some patients benefit from immune checkpoint therapy, current treatment methods rely mainly on chemotherapy. It is imperative to develop predictors of efficacy and identify individuals who will be sensitive to particular treatment regimens.
View Article and Find Full Text PDFJMIR Res Protoc
January 2025
Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada.
Background: Telehomecare monitoring (TM) in patients with cancer is a complex intervention. Research shows variations in the benefits and challenges TM brings to equitable access to care, the therapeutic relationship, self-management, and practice transformation. Further investigation into these variations factors will improve implementation processes and produce effective outcomes.
View Article and Find Full Text PDFCurr Atheroscler Rep
January 2025
Department of Medicine, Division of Cardiology, University of California, Los Angeles, Los Angeles, CA, USA.
Purpose Of Review: Discuss the relationship between pregnancy complications and long-term atherosclerotic cardiovascular disease (ASCVD) risk.
Recent Findings: A large body of research confirms an association between pregnancy complications and increased short and long-term ASCVD risk and seeks to understand mechanisms for these associations. Social determinants of health continue to have a critical impact on the prevalence of adverse pregnancy outcomes (APOs) and long term ASCVD risk.
Cardiovasc Drugs Ther
January 2025
Department of Cardiology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, 16766 Jingshi Road, Jinan City, 250014, China.
Background: Glucagon-like peptide-1 (GLP-1) is a crucial incretin hormone secreted by intestinal endocrine L cells. Given its pivotal physiological role, researchers have developed GLP-1 receptor agonists (GLP-1 RAs) through structural modifications. These analogues display pharmacological effects similar to those of GLP-1 but with augmented stability and are regarded as an effective means of regulating blood glucose levels in clinical practice.
View Article and Find Full Text PDFCurr Oncol Rep
January 2025
Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Purpose Of Review: This review addresses the current treatment paradigm and new advancements in the management of microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) esophagogastric cancer (EGC).
Recent Findings: While chemotherapy and surgery remain the cornerstone of EGC treatment, MSI-H/dMMR tumors harbor high tumor mutational burden and represent a subset of patients who benefit from immune checkpoint inhibitors (ICI). ICI has been incorporated in the front line setting with and without chemotherapy for advanced disease.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!